Dishman Carbogen Amcis Q2 FY27: revenue down 22.3% to ₹507 Cr, net loss ₹67 Cr
Results · 16 Nov 2026 · Dishman Carbogen Amcis (DCAL)
| Q2 FY27 | ₹ Cr | YoY |
|---|---|---|
| Revenue | 507 | -22.3% |
| Operating profit | 46 | -69.1% |
| Net profit | -67 | -202.2% |
Q2 FY27 revenue fell 22% year-on-year to INR 507 crores with EBITDA of INR 46 crores, while H1 revenue declined 13% to INR 1,185 crores and EBITDA stood at INR 106 crores.
CDMO Q2 revenue was INR 388 crores at a 12.3% margin versus 25% last year, while Marketable Molecules Q2 revenue fell to INR 118 crores due to lower vitamin D analogs sales.
Management expects no FY27 revenue growth and full-year EBITDA margins near 15% to 16%, but estimates at least 10% to 12% annual growth and over 20% to 21% margins for FY28-29.
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.